The isomers, aloe-emodin and emodin, possess differential inhibitory activities against CYP1B1 enzyme

Abstract

Aloe-emodin, known as a 3-hydroxymethyl-chrysazin, is one of anthraquinones mainly found in Rheum officinale Baill, Rheum palmatum L and Rheum tanguticum Maxim. Ex BALF. In recent studies, aloe-emodin possesses many pharmacological effects, including antitumor, antibacterial, antiviral, anti-inflammatory, cardiovascular protection, liver protection, immune regulation, estrogenic activity as a phytoestrogen, and so on. Cytochrome P450 (CYP) 1B1 (CYP1B1), as a major estrogen metabolizing enzyme, can metabolize 17β-estradiol (E2) to 4-hydroxy-E2 (4-OH-E2), which cause DNA damage and lead to tumor. Few studies have found that anthraquinones possess inhibitory activity against CYP1B1 enzyme. In this study, compared with emodin (3-Hydroxy-6-methyl-chrysazin, C15H10O5), the inhibition of aloe-emodin (3-hydroxymethyl-chrysazin, C15H10O5) on the activity of CYP1B1 was studied. The molecular mechanism of inhibition and the structure–activity relationship were also discussed. Although isomeric, the IC50 values of aloe-emodin and emodin were 0.192 ± 0.015 nM and 0.067 ± 0.003 µM, indicating the inhibition of aloe-emodin was about 350times stronger than that of emodin. Through structure–activity relationship analyses, it revealed the difference of inhibitory activity only due to different hydroxyl positions. When the hydroxyl group is transferred from the chrysazin skeleton to the methyl group, the hydrogen bond formed by this structure with the CYP1B1 protein can change the protein conformation, which may interfere with the binding of the substrate to CYP1B1 protein active site pocket and inhibit the catalytic activity of the CYP1B1 protein. Although the hydroxyl position changed, the inhibition mechanism did not change, all of which were mixed inhibition. This study reveals an anti-tumor mechanism of the anthraquinone compound aloe-emodin.